Evaxion Biotech Stock Forum

$Evaxion Biotech (EVAX.US)$
Evaxion Biotech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(9.99%),Steven Boyd(9.99%)
SEC·

$Evaxion Biotech (EVAX.US)$
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology™ platform trigger targeted immune responses
Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virus
Evaxion is advancing these new findings to develop a multi-component CMV vaccine candidate
About 1 in 2...

$Evaxion Biotech (EVAX.US)$
Evaxion will attend the largest and most established European meeting on vaccine R&D in Barcelona, Spain, showcasing their AI Immunology platform on October 30th and 31th.

$Evaxion Biotech (EVAX.US)$
International Society for Vaccines - ISV 2024, Seoul, South Korea, on day 2 had a super exciting session on AI and machine learning for vaccine R&D. The leaders in the field such as Andreas Holm Mattsson, from EVAXION Biotech A/S, Denmark gave an exciting overview of the AI Immunology platform.

$Evaxion Biotech (EVAX.US)$ Evaxion Says Data From Three Separate Clinical Trials Documents The Ability Of The AI-immunology Platform To Select Clinically Relevant Vaccine Targets

$Evaxion Biotech (EVAX.US)$
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Evaxion Biotech A/S (NASDAQ: EVAX) has reported strong validation of its AI-Immunology™ platform in multiple clinical trials. The company, specializing in AI-powered vaccine development, has gathered evidence from three separate clinical trials demonstrating the platform's ability to select clinically relevant vaccine targets.
Key findings include:
Statistically significant correla...

$Evaxion Biotech (EVAX.US)$ Reuter
2 mins ago
Rcent Clinical Data Confirms Significantly Improved Predictive Power of Evaxion's AI-Immunology™ Platform

$Evaxion Biotech (EVAX.US)$
Evaxion significantly expands vaccine development collaboration with MSD
Agreement provides MSD with options to license Evaxion's preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3
Evaxion will host a conference call and webcast to discuss the agreement on September 27, 2024
COPENHAGEN, Denmark, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powe...

$Evaxion Biotech (EVAX.US)$ Evaxion Launches Improved AI-Immunology™ Platform for Vaccine Antigen Prediction

$Evaxion Biotech (EVAX.US)$ down it goes